OXTENDA HA

Welcome to the Brand page for “OXTENDA HA”, which is offered here for (based on 44(e)) (based on intent to use) drug delivery systems, tablets, capsules, and pellets that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations for humans; drug delivery systems, oral solid dose tablets or capsules that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations for humans; pharmaceutical preparations, tablets, capsules, and pellets for humans that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations, all sold as an integral component of pharmaceutical preparations for use in the treatment of attention deficit disorders, central nervous system disorders, depression, diabetes, epilepsy, gastric disorders, gastro-intestinal tract disorders, hypertension, infection, inflammation, pain, rheumatoid arthritis and rhinitis;ha;(based on 44(e)) (based on intent to use) research and development services for others in the pharmaceutical sciences, the development and application of drug delivery technologies to the development of controlled, timed release and/or targeted release pharmaceutical preparations;.

Its status is currently believed to be active. Its class is unavailable. “OXTENDA HA” is believed to be currently owned by “Intellipharmaceutics Corp.”

Owner:
INTELLIPHARMACEUTICS CORP.
Owner Details
Description:
(Based on 44(e)) (Based on Intent to Use) Drug delivery systems, tablets, capsules, and pellets that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations for humans; drug delivery systems, oral solid dose tablets or capsules that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations for humans; pharmaceutical preparations, tablets, capsules, and pellets for humans that provide controlled timed release and/or targeted release of the active ingredients of pharmaceutical preparations, all sold as an integral component of pharmaceutical preparations for use in the treatment of attention deficit disorders, central nervous system disorders, depression, diabetes, epilepsy, gastric disorders, gastro-intestinal tract disorders, hypertension, infection, inflammation, pain, rheumatoid arthritis and rhinitis;HA;(Based on 44(e)) (Based on Intent to Use) Research and development services for others in the pharmaceutical sciences, the development and application of drug delivery technologies to the development of controlled, timed release and/or targeted release pharmaceutical preparations;
Categories: BASED ON E BASED ON